Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer

Cancer Research
Vanessa F MerinoSaraswati Sukumar

Abstract

Efforts to induce the differentiation of cancer stem cells through treatment with all-trans retinoic acid (ATRA) have yielded limited success, partially due to the epigenetic silencing of the retinoic acid receptor (RAR)-β The histone deacetylase inhibitor entinostat is emerging as a promising antitumor agent when added to the standard-of-care treatment for breast cancer. However, the combination of epigenetic, cellular differentiation, and chemotherapeutic approaches against triple-negative breast cancer (TNBC) has not been investigated. In this study, we found that combined treatment of TNBC xenografts with entinostat, ATRA, and doxorubicin (EAD) resulted in significant tumor regression and restoration of epigenetically silenced RAR-β expression. Entinostat and doxorubicin treatment inhibited topoisomerase II-β (TopoII-β) and relieved TopoII-β-mediated transcriptional silencing of RAR-β Notably, EAD was the most effective combination in inducing differentiation of breast tumor-initiating cells in vivo Furthermore, gene expression analysis revealed that the epithelium-specific ETS transcription factor-1 (ESE-1 or ELF3), known to regulate proliferation and differentiation, enhanced cell differentiation in response to EAD triple...Continue Reading

References

Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
May 21, 2003·Genes & Development·Gabriela DontuMax S Wicha
Mar 31, 2004·Proceedings of the National Academy of Sciences of the United States of America·Charlotte KuperwasserRobert A Weinberg
Jul 14, 2005·British Journal of Cancer·T LiuG M Marshall
Mar 14, 2007·Cancer Cell·Michail ShipitsinKornelia Polyak
May 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Suresh S RamalingamChandra P Belani
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Chad J CreightonJenny C Chang
Oct 7, 2009·Cell Cycle·Christophe GinestierEmmanuelle Charafe-Jauffret
Sep 4, 2010·Breast Cancer Research : BCR·Aleix PratCharles M Perou
Nov 16, 2010·Annual Review of Pathology·Xiao-Han Tang, Lorraine J Gudas
Dec 30, 2010·BMB Reports·Hyun Sub CheongHyoung Doo Shin
Jan 22, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mei-Chuan ChenChing-Shih Chen
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Dec 14, 2011·Cell·Sandeep Kumar, Gregg Duester
Dec 14, 2011·Laboratory Investigation; a Journal of Technical Methods and Pathology·Jordan R OliverJim Hu
Jul 28, 2012·Journal of Mammary Gland Biology and Neoplasia·Roisin Connolly, Vered Stearns
Jan 17, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roisin M ConnollySaraswati Sukumar
Aug 29, 2013·Scientific Reports·Poornima Bhat-NakshatriHarikrishna Nakshatri
Oct 22, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marion A SalvadorChristophe Ginestier
Jan 3, 2014·The Journal of Clinical Investigation·Alison C West, Ricky W Johnstone
May 3, 2014·Therapeutic Advances in Medical Oncology·S Lindsey DavisJennifer R Diamond

❮ Previous
Next ❯

Citations

Sep 14, 2016·Leukemia Research·Kelly J NorsworthyB Douglas Smith
Apr 4, 2017·Oncogenesis·Sö-G PohlA Dharmarajan
Jul 19, 2017·Expert Opinion on Investigational Drugs·Dario TrapaniGiuseppe Curigliano
Jun 1, 2018·Molecular Biology of the Cell·Andrei KucharavyRong Li
Jun 24, 2020·Cancer Metastasis Reviews·Joy JonkersSaraswati Sukumar
Sep 12, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ian Y LukJohn M Mariadason
Jun 21, 2019·Medicinal Research Reviews·Daniela TomaselliAntonello Mai
Jun 21, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chaofeng MuHaifa Shen
Jan 12, 2021·Molecular Carcinogenesis·Naing L ShanNanjoo Suh
Oct 2, 2021·Frontiers in Cell and Developmental Biology·Wei LiDa Pang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.